BioLineRx Ltd.
BLRX
$3.39
$0.020.56%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 145.88% | -54.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 145.88% | -54.57% | |||
| Cost of Revenue | 137.50% | -52.38% | |||
| Gross Profit | 148.05% | -55.10% | |||
| SG&A Expenses | -23.05% | 34.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.77% | 35.91% | |||
| Operating Income | 11.28% | -53.42% | |||
| Income Before Tax | -15.74% | -128.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.74% | -128.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 15.98% | -- | |||
| Net Income | -15.60% | -41.76% | |||
| EBIT | 11.28% | -53.42% | |||
| EBITDA | 12.41% | -59.45% | |||
| EPS Basic | -20.00% | -25.00% | |||
| Normalized Basic EPS | 0.00% | 0.00% | |||
| EPS Diluted | -20.00% | -25.00% | |||
| Normalized Diluted EPS | 0.00% | 0.00% | |||
| Average Basic Shares Outstanding | -0.08% | 2.12% | |||
| Average Diluted Shares Outstanding | -0.08% | 2.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||